David Alan Pool
Directeur Financier/CFO chez OcuNexus Therapeutics, Inc.
Profil
David Alan Pool is currently the Director at OMNIlife science, Inc. and holds the position of Chief Operating & Financial Officer at InflammX Therapeutics, Inc. He previously served as the Chief Financial Officer at OcuNexus Therapeutics, Inc. and CoDa Therapeutics (NZ) Ltd.
He was also the Chief Operating & Financial Officer at Protemix Corp.
Ltd.
from 2010 to 2011.
Mr. Pool is a Member of the New Zealand Institute of Chartered Accountants.
He has also served as a Director at Birnie Capital Partners Ltd.
and OMNI Orthopaedics, Inc. Mr. Pool completed his undergraduate degree from the University of Canterbury.
Postes actifs de David Alan Pool
| Sociétés | Poste | Début |
|---|---|---|
New Zealand Institute of Chartered Accountants
 New Zealand Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services New Zealand Institute of Chartered Accountants operates as an institute of chartered accountants. The company is headquartered in Wellington, New Zealand. | Corporate Officer/Principal | 25/03/2009 |
CoDa Therapeutics (NZ) Ltd.
 CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Directeur Financier/CFO | 01/07/2008 |
OcuNexus Therapeutics, Inc.
 OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Directeur Financier/CFO | 25/03/2010 |
OMNIlife science, Inc.
 OMNIlife science, Inc. Medical SpecialtiesHealth Technology OMNIlife science, Inc. manufactures orthopedic, prosthetic and other related products. The firm products are used in hip and knee replacement, joint pain and robotic surgery. The company was founded by Edward J. Cheal and George B. Cipolletti in 1999 and is headquartered in Raynham, MA. | Directeur/Membre du Conseil | - |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur Financier/CFO | 01/12/2020 |
Anciens postes connus de David Alan Pool
| Sociétés | Poste | Fin |
|---|---|---|
Protemix Corp. Ltd.
 Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Directeur Financier/CFO | 13/07/2011 |
OMNI Orthopaedics, Inc.
 OMNI Orthopaedics, Inc. Medical SpecialtiesHealth Technology OMNI Orthopaedics, Inc. designs, manufactures, and distributes orthopedic implants. The company was founded by David L. Lasalle, George B. Cipoletti and Edward J. Cheal on December 22, 2008 and is headquartered in Taunton, MA. | Directeur/Membre du Conseil | - |
KPMG (Auckland)
 KPMG (Auckland) Miscellaneous Commercial ServicesCommercial Services KPMG (Auckland) provides accounting services. It also provides audit, tax and advisory services, and industry insight to help other companies to negotiate risks and perform in today's business environments. The company was founded in 1987 and is headquartered in Auckand, New Zealand. | Treasurer | - |
Birnie Capital Partners Ltd.
 Birnie Capital Partners Ltd. Investment Banks/BrokersFinance Birnie Capital Partners Ltd. was provided investment banking services. The company was incorporated on March 31, 1989 and was headquartered in Auckland, New Zealand. | Directeur/Membre du Conseil | - |
Formation de David Alan Pool
| University of Canterbury | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Health Technology |
New Zealand Institute of Chartered Accountants
New Zealand Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services New Zealand Institute of Chartered Accountants operates as an institute of chartered accountants. The company is headquartered in Wellington, New Zealand. | Commercial Services |
Birnie Capital Partners Ltd.
Birnie Capital Partners Ltd. Investment Banks/BrokersFinance Birnie Capital Partners Ltd. was provided investment banking services. The company was incorporated on March 31, 1989 and was headquartered in Auckland, New Zealand. | Finance |
KPMG (Auckland)
KPMG (Auckland) Miscellaneous Commercial ServicesCommercial Services KPMG (Auckland) provides accounting services. It also provides audit, tax and advisory services, and industry insight to help other companies to negotiate risks and perform in today's business environments. The company was founded in 1987 and is headquartered in Auckand, New Zealand. | Commercial Services |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Health Technology |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
OMNI Orthopaedics, Inc.
OMNI Orthopaedics, Inc. Medical SpecialtiesHealth Technology OMNI Orthopaedics, Inc. designs, manufactures, and distributes orthopedic implants. The company was founded by David L. Lasalle, George B. Cipoletti and Edward J. Cheal on December 22, 2008 and is headquartered in Taunton, MA. | Health Technology |
OMNIlife science, Inc.
OMNIlife science, Inc. Medical SpecialtiesHealth Technology OMNIlife science, Inc. manufactures orthopedic, prosthetic and other related products. The firm products are used in hip and knee replacement, joint pain and robotic surgery. The company was founded by Edward J. Cheal and George B. Cipolletti in 1999 and is headquartered in Raynham, MA. | Health Technology |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |